RESUMEN
BACKGROUND: Soft tissue sarcomas (STS) are generally considered non-immunogenic, although specific subtypes respond to immunotherapy. Antitumour response within the tumour microenvironment relies on a balance between inhibitory and activating signals for tumour-infiltrating lymphocytes (TILs). This study analysed TILs and immune checkpoint molecules in STS, and assessed their prognostic impact regarding local recurrence (LR), distant metastasis (DM), and overall survival (OS). METHODS: One-hundred and ninety-two surgically treated STS patients (median age: 63.5 years; 103 males [53.6%]) were retrospectively included. Tissue microarrays were constructed, immunohistochemistry for PD-1, PD-L1, FOXP3, CD3, CD4, and CD8 performed, and staining assessed with multispectral imaging. TIL phenotype abundance and immune checkpoint markers were correlated with clinical and outcome parameters (LR, DM, and OS). RESULTS: Significant differences between histology and all immune checkpoint markers except for FOXP3+ and CD3-PD-L1+ cell subpopulations were found. Higher levels of PD-L1, PD-1, and any TIL phenotype were found in myxofibrosarcoma as compared to leiomyosarcoma (all p < 0.05). The presence of regulatory T cells (Tregs) was associated with increased LR risk (p = 0.006), irrespective of margins. Other TILs or immune checkpoint markers had no significant impact on outcome parameters. CONCLUSIONS: TIL and immune checkpoint marker levels are most abundant in myxofibrosarcoma. High Treg levels are independently associated with increased LR risk, irrespective of margins.
Asunto(s)
Antígeno B7-H1/metabolismo , Fibrosarcoma/patología , Leiomiosarcoma/patología , Mixosarcoma/patología , Receptor de Muerte Celular Programada 1/metabolismo , Linfocitos T Reguladores/inmunología , Anciano , Biomarcadores de Tumor/metabolismo , Complejo CD3/metabolismo , Antígenos CD4/metabolismo , Antígenos CD8/metabolismo , Femenino , Fibrosarcoma/inmunología , Factores de Transcripción Forkhead/metabolismo , Humanos , Leiomiosarcoma/inmunología , Masculino , Persona de Mediana Edad , Mixosarcoma/inmunología , Estudios Retrospectivos , Análisis de Matrices Tisulares , Microambiente Tumoral , Regulación hacia ArribaRESUMEN
Appendiceal neoplasms are rare, occurring in <1.4% of all appendicectomy specimens. Carcinoid tumours and adenocarcinomas comprise the majority of cases, however, lymphomas or sarcomas may also arise within the appendix. Appendiceal leiomyosarcomas are rare and to date, there remains a relative dearth of cases reported in the literature. Leiomyosarcomas are derived from the smooth muscle cells or mesenchymal stem cells committed to this line of differentiation. However, their pathogenesis and underlying genetic mechanism remains to be fully elucidated. Unbalanced karyotypic defects are the only shared features observed across different leiomyosarcoma subtypes. Children with AIDS have a higher incidence compared with adults, where the main pathology in individuals with HIV is Kaposi's sarcoma and B-cell lymphoma. Although surgical excision with clear margins remains the treatment of choice, a good response to treatment with gemcitabine, docetaxel and trabectedin has been observed. The authors present the case of a 23-year-old female presenting to the emergency department with acute appendicitis. She underwent a laparoscopic converted to an open appendectomy. Her operation was complicated by a pelvic collection requiring percutaneous drainage and an ileus. Histopathological examination confirmed the diagnosis of a leiomyosarcoma, a rare mesenchymal tumour presenting in individuals with immune suppression. HIV serology was positive and she commenced anti-retroviral therapy. She remains under review in the Department of HIV Medicine.
Asunto(s)
Neoplasias del Apéndice/diagnóstico , Apendicitis/diagnóstico , Infecciones por VIH/diagnóstico , Leiomiosarcoma/diagnóstico , Lesión Renal Aguda , Apendicectomía , Neoplasias del Apéndice/inmunología , Neoplasias del Apéndice/patología , Neoplasias del Apéndice/cirugía , Diagnóstico Diferencial , Femenino , Infecciones por VIH/inmunología , Humanos , Hipopotasemia , Ileus , Huésped Inmunocomprometido , Leiomiosarcoma/inmunología , Leiomiosarcoma/patología , Leiomiosarcoma/cirugía , Complicaciones Posoperatorias , Infección de la Herida Quirúrgica , Adulto JovenRESUMEN
Reactivation of the anti-tumor response has shown substantial progress in aggressive tumors such as melanoma and lung cancer. Data on less common histotypes are scanty. Immune checkpoint inhibitor therapy has been applied to few cases of uterine leiomyosarcomas, of which the immune cell composition was not examined in detail. We analyzed the inflammatory infiltrate of 21 such cases in high-dimensional, single cell phenotyping on routinely processed tissue. T-lymphoid cells displayed a composite phenotype common to all tumors, suggestive of antigen-exposure, acute and chronic exhaustion. To the contrary, myelomonocytic cells had case-specific individual combinations of phenotypes and subsets. We identified five distinct monocyte-macrophage cell types, some not described before, bearing immunosuppressive molecules (TIM3, B7H3, VISTA, PD1, PDL1). Detailed in situ analysis of routinely processed tissue yields comprehensive information about the immune status of sarcomas. The method employed provides equivalent information to extractive single-cell technology, with spatial contexture and a modest investment.
Asunto(s)
Inmunidad Adaptativa , Biomarcadores de Tumor/inmunología , Inmunidad Innata , Leiomiosarcoma/inmunología , Análisis de la Célula Individual/métodos , Neoplasias Uterinas/inmunología , Adulto , Anciano , Antígenos B7/metabolismo , Antígeno B7-H1/metabolismo , Femenino , Receptor 2 Celular del Virus de la Hepatitis A/metabolismo , Humanos , Persona de Mediana Edad , Monocitos/metabolismo , Receptor de Muerte Celular Programada 1 , Linfocitos T/metabolismoRESUMEN
The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue microarrays (TMA) in studies that profile TIL burden is attractive but given the potential for intra-tumoural heterogeneity to introduce sampling errors, the adequacy of this approach is undetermined. In this study, we assessed the histological inter- and intra-tumoural heterogeneity in TIL burden within a retrospective cohort of primary LMS specimens. Using a virtual TMA approach, we also analysed the optimal number of TMA cores required to provide an accurate representation of TIL burden in a full tissue section. We establish that LMS have generally low and spatially homogenous TIL burdens, although a small proportion exhibit higher levels and more heterogeneous distribution of TILs. We show that a conventional and practical number (e.g. ≤3) of TMA cores is adequate for correct ordinal categorisation of tumours with high or low TIL burden, but that many more cores (≥11) are required to accurately estimate absolute TIL numbers. Our findings provide a benchmark for the design of future studies aiming to define the clinical relevance of the immune microenvironments of LMS and other sarcoma subtypes.
Asunto(s)
Leiomiosarcoma/inmunología , Linfocitos Infiltrantes de Tumor/citología , Neoplasias de los Tejidos Blandos/inmunología , Análisis de Matrices Tisulares , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/análisis , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Estudios Retrospectivos , Microambiente TumoralRESUMEN
Immunotherapies targeting the PD-1/PD-L1 checkpoint axis are of growing interest for the treatment of mesenchymal neoplasms. However, PD-L1 expression and tumor-associated lymphocytes have not been well-investigated in uterine smooth muscle tumors. Forty-nine uterine smooth muscle tumors (23 leiomyosarcomas, 8 smooth muscle tumors of uncertain malignant potential [STUMP], 7 atypical leiomyomas, and 11 benign leiomyomas) were evaluated for tumoral and tumor-associated immune PD-L1 expression and tumor-associated T-cell infiltration. ALK immunohistochemistry was performed to exclude inflammatory myofibroblastic tumors. Tumor PD-L1 expression was seen in 70% of leiomyosarcomas and 14% of atypical leiomyomas; no cases of STUMP or benign leiomyoma demonstrated tumoral PD-L1. PD-L1 positivity was seen in tumor-associated immune cells in 78% of leiomyosarcomas, 25% of STUMP, no cases of atypical leiomyomas, and 9% of benign leiomyomas. Of the 23 leiomyosarcomas, 15 (65%) had a combined positive score ≥1, while of the 26 other uterine smooth muscle tumors, only 2 (8%) had a combined positive score ≥1. Tumor-associated CD8+ cells were highest among leiomyosarcomas (mean: 87/high-power fields vs. 17/high-power fields for nonleiomyosarcomas), and were significantly associated with PD-L1 expression. One PD-L1, CD8-enriched leiomyosarcoma showed an ALK overexpression suggesting possible classification as inflammatory myofibroblastic tumor, but otherwise lacked morphologic features of this entity. Leiomyosarcomas demonstrate significantly higher PD-L1 expression and cytotoxic T-cell infiltration when compared with other uterine smooth muscle tumors. These data suggest the possibility that treatment with targeted immunotherapy may be appropriate in a selected population of patients with leiomyosarcoma and, potentially, in related tumors bearing ALK rearrangements.
Asunto(s)
Antígeno B7-H1/análisis , Biomarcadores de Tumor/análisis , Leiomioma/inmunología , Leiomiosarcoma/inmunología , Linfocitos Infiltrantes de Tumor/inmunología , Tumor de Músculo Liso/inmunología , Linfocitos T Citotóxicos/inmunología , Neoplasias Uterinas/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Quinasa de Linfoma Anaplásico/análisis , Antineoplásicos Inmunológicos/uso terapéutico , Femenino , Humanos , Inmunoterapia , Leiomioma/tratamiento farmacológico , Leiomioma/patología , Leiomiosarcoma/tratamiento farmacológico , Leiomiosarcoma/patología , Linfocitos Infiltrantes de Tumor/patología , Persona de Mediana Edad , Pronóstico , Tumor de Músculo Liso/tratamiento farmacológico , Tumor de Músculo Liso/patología , Linfocitos T Citotóxicos/patología , Neoplasias Uterinas/tratamiento farmacológico , Neoplasias Uterinas/patología , Adulto JovenRESUMEN
Despite originating from several different tissues, soft-tissue sarcomas (STS) are often grouped together as they share mesenchymal origin and treatment guidelines. Also, with some exceptions, a common denominator is that when the tumor cannot be cured with surgery, the efficacy of current therapies is poor and new treatment modalities are thus needed. We have studied the combination of a capsid-modified oncolytic adenovirus CGTG-102 (Ad5/3-D24-GMCSF) with doxorubicin, with or without ifosfamide, the preferred first-line chemotherapeutic options for most types of STS. We show that CGTG-102 and doxorubicin plus ifosfamide together are able to increase cell killing of Syrian hamster STS cells over single agents, as well as upregulate immunogenic cell death markers. When tested in vivo against established STS tumors in fully immunocompetent Syrian hamsters, the combination was highly effective. CGTG-102 and doxorubicin (without ifosfamide) resulted in synergistic antitumor efficacy against human STS xenografts in comparison with single agent treatments. Doxorubicin increased adenoviral replication in human and hamster STS cells, potentially contributing to the observed therapeutic synergy. In conclusion, the preclinical data generated here support clinical translation of the combination of CGTG-102 and doxorubicin, or doxorubicin plus ifosfamide, for the treatment of STS, and provide clues on the mechanisms of synergy.
Asunto(s)
Adenoviridae/inmunología , Antibióticos Antineoplásicos/uso terapéutico , Doxorrubicina/uso terapéutico , Leiomiosarcoma/terapia , Melanoma Experimental/terapia , Virus Oncolíticos/inmunología , Animales , Antibióticos Antineoplásicos/farmacología , Línea Celular Tumoral , Supervivencia Celular , Terapia Combinada , Cricetinae , Doxorrubicina/farmacología , Sinergismo Farmacológico , Femenino , Humanos , Ifosfamida/farmacología , Ifosfamida/uso terapéutico , Leiomiosarcoma/inmunología , Masculino , Melanoma Experimental/inmunología , Mesocricetus , Ratones , Ratones Endogámicos C57BL , Ratones Desnudos , Viroterapia Oncolítica , Sarcoma , Replicación Viral , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Human adenoviruses are known to persist in T-lymphocytes of tonsils, adenoids and intestinal tract. The oncogenic potential of different adenovirus types has been widely studied in rodents, in which adenovirus inoculation can induce multiple tumors such as undifferentiated sarcomas, adenocarcinomas and neuroectodermal tumors. However, the oncogenic potential of this virus has never been proven in human subjects. Using a highly sensitive broad-spectrum qRT-PCR, we have screened a set of different human sarcomas including leiomyosarcoma, liposarcoma and gastro intestinal stroma tumors. Primers binding the viral oncogene E1A and the capsid-coding gene Hexon were used to detect the presence of adenovirus DNA in tumor samples. We found that 18% of the tested leiomyosarcomas and 35% of the liposarcomas were positive for the presence of adenovirus DNA, being species C types the most frequently detected adenoviruses. However, only in one sample of the gastro intestinal stroma tumors the virus DNA could be detected. The occurrence of adenovirus in the tumor sections was confirmed by subsequent fluorescence in-situ-hybridization analysis and co-staining with the transcription factor Bcl11b gives evidence for the presence of the virus in infiltrating T-lymphocytes within the tumors. Together these data underline, for the first time, the persistence of adenovirus in T-lymphocytes infiltrated in muscular and fatty tissue tumor samples. If an impaired immune system leads to the viral persistence and reactivation of the virus is involved in additional diseases needs further investigation.
Asunto(s)
Adenovirus Humanos/fisiología , Leiomiosarcoma/virología , Liposarcoma/virología , Linfocitos T/virología , Proteínas E1A de Adenovirus/genética , Secuencia de Bases , Interacciones Huésped-Patógeno , Humanos , Hibridación Fluorescente in Situ , Leiomiosarcoma/inmunología , Leiomiosarcoma/patología , Liposarcoma/inmunología , Liposarcoma/patología , Técnicas de Diagnóstico Molecular , Datos de Secuencia Molecular , Tipificación Molecular , Reacción en Cadena en Tiempo Real de la Polimerasa , Análisis de Secuencia de ADN , Carga ViralRESUMEN
PURPOSE OF REVIEW: In immunodeficiency, an increased sarcoma risk is confirmed for Kaposi's sarcoma. Whether rates of other sarcoma subtypes are elevated in the setting of immunodeficiency is not known. We therefore reviewed published case reports on HIV and AIDS patients and organ transplant recipients with sarcomas. For comparison, we assessed sarcomas in the U.S. general population using Surveillance Epidemiology End Results (SEER) data. RECENT FINDINGS: A total of 176 non-Kaposi sarcoma were identified, 75 in people with HIV and AIDS and 101 in transplant recipients. Leiomyosarcomas (nâ=â101) were the most frequently reported sarcomas, followed by angiosarcomas (nâ=â23) and fibrohistiocytic tumors (nâ=â17). Leiomyosarcomas were reported with two age peaks, in children and young adults. Epstein-Barr virus (EBV) was detected in the tumor cells in 85 and 88% of leiomyosarcomas in HIV-infected people and transplant recipients, respectively. Angiosarcomas and fibrohistiocytic tumors were most frequently reported in men. Among kidney transplant recipients, 20% of sarcomas arose at the site of an arteriovenous fistula. In comparison, leiomyoscarcomas, angiosarcomas, and fibrohistiocytic tumors comprised 16.9, 3.8, and 18.7% of sarcomas in the U.S. general population. SUMMARY: Leiomyosarcoma and angiosarcoma may occur disproportionately in immunodeficiency. Leiomyosarcomas appear causatively linked to EBV, whereas angiosarcomas might be correlated with an arteriovenous fistula. Additional studies are necessary to understand the contribution of immunodeficiency to the cause of these sarcomas.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/inmunología , Infecciones por VIH/inmunología , Sarcoma/inmunología , Sarcoma/virología , Síndrome de Inmunodeficiencia Adquirida/epidemiología , Infecciones por VIH/epidemiología , Hemangiosarcoma/epidemiología , Hemangiosarcoma/inmunología , Hemangiosarcoma/virología , Histiocitoma Fibroso Maligno/epidemiología , Histiocitoma Fibroso Maligno/inmunología , Histiocitoma Fibroso Maligno/virología , Humanos , Leiomiosarcoma/epidemiología , Leiomiosarcoma/inmunología , Leiomiosarcoma/virología , Programa de VERF , Sarcoma/epidemiología , Sarcoma de Kaposi/epidemiología , Sarcoma de Kaposi/inmunología , Sarcoma de Kaposi/virología , Estados Unidos/epidemiologíaRESUMEN
Uterine leiomyosarcoma comprises <1 % of uterine malignancies and is known for its clinically aggressive course. Extrapelvic recurrences are common and often lethal. No adjuvant therapies have been shown to significantly improve overall survival, highlighting the need for new and novel therapies. Our objective was to determine whether GD2-specific immunocytokine therapy may be explored for the treatment for uterine leiomyosarcoma. To do so, frozen tissue sections were obtained from the Gynecologic Oncology Group tumor bank and evaluated by immunohistochemistry (IHC) for GD2 expression using both the parent mouse monoclonal antibody 14G2A and immunocytokine 14.18-IL2 generated from the 14G2A sequence. Immunoreactivity was detected by avidin-biotin complex with DAB substrate. Specimens were reviewed by a pathologist with light microscopy and classified as negative, 1+, 2+ or 3+, compared to human melanoma cells as positive control and tissue incubated in the absence of primary antibody as negative control. GD2 was diffusely present in all evaluable samples. 10 tumors (67 %) demonstrated 3+ IHC intensity for GD2, two tumors (13 %) demonstrated 2+ intensity, and 3 (20 %) tumors demonstrated 1+ intensity. Eleven cases had sufficient tissue to assess 14.18-IL2 binding. All 11 cases bound 14.18-IL2 in a pattern identical to the parent antibody. Uterine leiomyosarcoma diffusely express GD2 and bind the therapeutic immunocytokine 14.18-IL2. This warrants further exploration to determine whether immunocytokine therapy may have a clinical role in the management of these aggressive tumors.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Gangliósidos/biosíntesis , Interleucina-2/metabolismo , Leiomiosarcoma/inmunología , Leiomiosarcoma/terapia , Neoplasias Uterinas/inmunología , Neoplasias Uterinas/terapia , Animales , Anticuerpos Monoclonales/metabolismo , Femenino , Gangliósidos/inmunología , Humanos , Inmunohistoquímica , Inmunoterapia , Interleucina-2/inmunología , Leiomiosarcoma/metabolismo , Leiomiosarcoma/patología , Ratones , Estadificación de Neoplasias , Células Tumorales Cultivadas , Neoplasias Uterinas/metabolismo , Neoplasias Uterinas/patologíaRESUMEN
BACKGROUND: Multiple viruses have been associated with carcinogenesis in solid-organ transplant patients. Although Epstein-Barr virus (EBV) has been associated with lymphomas in immunocompromised patients, an association with smooth muscle tumors recently has been described. CASE: An EBV immunoglobulin G-positive woman underwent bilateral lung transplant for sarcoidosis. She was placed on immunosuppression and prophylaxis for opportunistic infections. She presented 5 months later with an EBV-positive uterine leiomyosarcoma. Postoperative therapy included a decrease in immunosuppression and antiviral therapy. Recurrence was noted after 1 year; the patient developed sepsis while undergoing chemotherapy and declined further therapy. CONCLUSION: Epstein-Barr virus-associated leiomyosarcoma can occur in the uterus in immunosuppressed patients.
Asunto(s)
Herpesvirus Humano 4/aislamiento & purificación , Huésped Inmunocomprometido , Leiomiosarcoma/virología , Trasplante de Pulmón/inmunología , Recurrencia Local de Neoplasia/virología , Neoplasias Uterinas/virología , Adulto , Resultado Fatal , Femenino , Humanos , Leiomiosarcoma/inmunología , Leiomiosarcoma/patología , Neoplasias Uterinas/inmunología , Neoplasias Uterinas/patologíaRESUMEN
Hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, c-Met, have been implicated in the growth and progression of a variety of solid human tumors. Thus, inhibiting HGF/SF:c-Met signaling may provide a novel therapeutic approach for treating human tumors. We have generated and characterized fully human monoclonal antibodies that bind to and neutralize human HGF/SF. In this study, we tested the effects of the investigational, human anti-human HGF/SF monoclonal antibody, AMG 102, and a mixture of mouse anti-human HGF/SF monoclonal antibodies (Amix) on HGF/SF-mediated cell migration, proliferation, and invasion in vitro. Both agents had high HGF/SF-neutralizing activity in these cell-based assays. The HGF/SF:c-Met pathway has been implicated in the growth of sarcomas; thus, we also investigated the effect of AMG 102 on the growth of human leiomyosarcoma (SK-LMS-1) in HGF/SF transgenic C3H severe combined immunodeficient mice engineered to express high levels of human HGF/SF, as well as tumor growth of an autocrine variant of the SK-LMS-1 cell line (SK-LMS-1TO) in nude mice. The results indicate that interrupting autocrine and/or paracrine HGF/SF:c-Met signaling with AMG 102 has profound antitumor effects. These findings suggest that blocking HGF/SF:c-Met signaling may provide a potent intervention strategy to treat patients with HGF/SF:c-Met-dependent tumors.
Asunto(s)
Anticuerpos Neutralizantes/uso terapéutico , Comunicación Autocrina , Factor de Crecimiento de Hepatocito/inmunología , Leiomiosarcoma/tratamiento farmacológico , Leiomiosarcoma/patología , Comunicación Paracrina , Proteínas Proto-Oncogénicas c-met/metabolismo , Animales , Anticuerpos Neutralizantes/farmacología , Comunicación Autocrina/efectos de los fármacos , Línea Celular , Proliferación Celular/efectos de los fármacos , Fibrinolisina/metabolismo , Humanos , Leiomiosarcoma/inmunología , Ligandos , Ratones , Ratones Transgénicos , Modelos Inmunológicos , Invasividad Neoplásica , Comunicación Paracrina/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Immunotherapy employs cytokines for modifying local inflammatory reactions. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to activate dendritic cells, macrophages, and granulocytes leading to clinical trials using GM-CSF-based cancer vaccine approaches. Interleukin-2 (IL-2) is an important T cell stimulatory cytokine approved as exogenous antitumor agent. The ALVAC viral vector system uses a recombinant canarypox virus for local gene expression. We report a phase I clinical trial using intratumoral administration of ALVAC GM-CSF or ALVAC IL-2 in skin metastases of melanoma or leiomyosarcoma. ALVAC GM-CSF and ALVAC IL-2 were injected at 107.12 and 106.92, 50% cell culture infectious dose in eight metastases with acceptable tolerability. Local and systemic inflammatory reactions were observed. The transgene determined the local infiltrate: GM-CSF induced monocyte and macrophage enrichment of the peritumoral inflammatory infiltrate, whereas IL-2 increased local T lymphocytes. Stable disease of injected lesions was seen after ALVAC GM-CSF application, whereas ALVAC IL-2 treatment led to partial regression in three out of eight injected tumors, accompanied by decreased expression of melanocytic antigens. Local GM-CSF expression could be induced. In summary, ALVAC GM-CSF and ALVAC IL-2 injections are safe and can mediate local biologic and immunologic effects.
Asunto(s)
Vacunas contra el Cáncer/uso terapéutico , Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Interleucina-2/uso terapéutico , Leiomiosarcoma/terapia , Melanoma/secundario , Melanoma/terapia , Neoplasias Cutáneas/terapia , Adulto , Anciano , Anciano de 80 o más Años , Vacunas contra el Cáncer/genética , Vacunas contra el Cáncer/inmunología , Células Dendríticas/inmunología , Femenino , Terapia Genética , Vectores Genéticos , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Factor Estimulante de Colonias de Granulocitos y Macrófagos/inmunología , Humanos , Inmunoterapia , Interleucina-2/genética , Interleucina-2/inmunología , Leiomiosarcoma/inmunología , Leiomiosarcoma/secundario , Macrófagos/inmunología , Masculino , Melanoma/inmunología , Melanoma/patología , Persona de Mediana Edad , Proteínas Recombinantes , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/secundario , Linfocitos T Citotóxicos/inmunología , Transgenes , Vacunas Virales/genética , Vacunas Virales/inmunología , Vacunas Virales/uso terapéuticoRESUMEN
Epstein-Barr virus (EBV) associated smooth muscle tumors (SMTs) have been described in patients with acquired immune deficiency syndrome (AIDS) and, more recently, in association with immunosuppression after solid-organ transplantation. We present the autopsy findings of multiple leiomyosarcomas (LMSs) in a 24-year old man who died 18 months after undergoing orthotopic cardiac transplantation for idiopathic cardiomyopathy. The recognition of EBV-driven LMS developing in cardiac transplant recipients in multiple unusual sites is crucial for the management of these patients and should include complete surgical removal anti-viral therapy and modulation of immunosuppression.
Asunto(s)
Infecciones por Virus de Epstein-Barr/complicaciones , Trasplante de Corazón , Herpesvirus Humano 4 , Terapia de Inmunosupresión/efectos adversos , Leiomiosarcoma/virología , Neoplasias Primarias Múltiples/virología , Adulto , Trasplante de Corazón/inmunología , Humanos , Leiomiosarcoma/inmunología , Leiomiosarcoma/patología , Masculino , Neoplasias Primarias Múltiples/inmunología , Neoplasias Primarias Múltiples/patología , Tumor de Músculo Liso/inmunología , Tumor de Músculo Liso/patología , Tumor de Músculo Liso/virologíaAsunto(s)
Células Epitelioides/patología , Leiomiosarcoma/patología , Neoplasias Uterinas/patología , Antígenos de Neoplasias , Biomarcadores de Tumor/análisis , Células Epitelioides/inmunología , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Leiomiosarcoma/clasificación , Leiomiosarcoma/genética , Leiomiosarcoma/inmunología , Antígenos Específicos del Melanoma , Proteínas de Neoplasias/análisis , Terminología como Asunto , Neoplasias Uterinas/clasificación , Neoplasias Uterinas/genética , Neoplasias Uterinas/inmunologíaRESUMEN
UNLABELLED: Primary pure ovarian leiomyosarcomas constitute a malignant subgroup of ovarian smooth muscle tumors which comprise only 1% of ovarian tumors. Their origin, etiology, histologic features, clinical behavior, and optimal treatment are still obscure. Malignant behavior is almost always associated with any 2 of coagulative necrosis, cellular atypia, and mitotic index greater than 10. Immunohistochemical and electron microscopic evaluations may improve diagnostic accuracy. Traditionally, International Federation of Gynecology and Obstetrics (FIGO) staging and treatment of ovarian sarcomas have been the same as for epithelial ovarian carcinomas. Although surgery was performed for all cases, the extent of surgery is debatable. Benefit and modality of adjuvant therapy is controversial. The prognosis of primary pure ovarian leiomyosarcomas is extremely poor depending on tumor stage, tumor size, grade, and mitotic index and mostly recurs in abdomen and pelvis. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING OBJECTIVES: After completion of this article, the reader should be able to state how rare primary ovarian leiomyosarcoma (POLMS) is, explain that because of its rarity the best diagnostic and treatment modalities are not conclusive, and recall that the authors reviewed the literature to bring the readership current on POLMS.
Asunto(s)
Leiomiosarcoma/inmunología , Leiomiosarcoma/patología , Neoplasias Ováricas/inmunología , Neoplasias Ováricas/patología , Anciano , Terapia Combinada , Femenino , Humanos , Inmunohistoquímica , Leiomiosarcoma/cirugía , Persona de Mediana Edad , Neoplasias Ováricas/cirugíaAsunto(s)
Pared Abdominal/patología , Infecciones por Virus de Epstein-Barr/inmunología , Huésped Inmunocomprometido , Leiomiosarcoma/inmunología , Lupus Eritematoso Sistémico/complicaciones , Infecciones Tumorales por Virus/inmunología , Adulto , Femenino , Herpesvirus Humano 4 , Humanos , Inmunohistoquímica , Inmunosupresores/uso terapéutico , Leiomiosarcoma/patología , Lupus Eritematoso Sistémico/tratamiento farmacológicoRESUMEN
OBJECTIVE: Smooth muscle tumors of uterus have been reported to contain considerable number of mast cells, especially cellular leiomyoma. However, to our knowledge the mechanism by which mast cells increased in them is not known. The purpose of this study was to reveal the different mast cell subsets in smooth muscle tumors of uterus and to investigate the mechanism of local increase of mast cells. METHODS: Tissue sections from 85 uterine smooth muscle tumors were studied using immunohistochemical double labeling techniques, including 40 cases of ordinary leiomyomas, 30 cases of cellular leiomyomas and 15 cases of leiomyosarcomas. The sections were double immunostained for mast cell tryptase and chymase, mast cell tryptase and ki-67, mast cell tryptase and chemokines (i.e., CCL2, CCL5, CCL11, TGFbeta), as well as tryptase and CCR3. RESULTS: MC(TC)-type of mast cells was the predominant type in ordinary leiomyoma and cellular leiomyoma, whereas MC(T)-type was seldom found in them. There was no MC(C) in smooth muscle tumors. The total intratumoral number of mast cells in cellular leiomyoma group was significantly higher than that in both leiomyosarcoma and ordinary leiomyoma (P<0.01). Mast cells proliferation was rarely detected in smooth muscle tumors, as revealed by constant negative labeling of the proliferation marker Ki-67 in mast cells. Almost all mast cells (tryptase positive) in smooth muscle tumors were also CCL2, CCL5, CCL11 and TGFbeta positive. Expressions of CCL5 and CCL11 in tumor cells in cellular leiomyoma were all significantly higher than that in both ordinary leiomyoma and leiomyosarcoma (P<0.01). While the expression of TGFbeta in tumor cells in cellular leiomyoma was not significantly different from that in ordinary leiomyoma, expression of CCL2 was not observed in smooth muscle tumor cells. There were positive correlations between CCL5 and the number of mast cells (r(s)=0.801, P<0.01) and between CCL11 and the number of mast cells (r(s)=0.744, P<0.01) in smooth muscle tumors as well. The vast majority of the mast cells in cellular leiomyoma were CCR3 positive. CONCLUSIONS: Using the monoclonal anti-mast cell tryptase antibody could detect all mast cells in smooth muscle tumor. The increased intratumoral mast cell counts in cellular leiomyoma might be the result of mast cells recruitment from the peripheral blood rather than local mast cells proliferation. CCL5 and CCL11, which are expressed by smooth muscle tumor cells, are possibly responsible for the recruitment of mast cells in uterine cellular leiomyoma. Whether they combine to CCR3 expressed by mast cells need further study.
Asunto(s)
Quimiocinas CC/biosíntesis , Leiomioma/inmunología , Leiomiosarcoma/inmunología , Mastocitos/inmunología , Neoplasias Uterinas/inmunología , Quimiocina CCL11 , Quimiocina CCL2/biosíntesis , Quimiocina CCL5 , Femenino , Humanos , Antígeno Ki-67/biosíntesis , Leiomioma/patología , Leiomiosarcoma/patología , Mastocitos/patología , Factor de Crecimiento Transformador beta/biosíntesis , Neoplasias Uterinas/patologíaRESUMEN
Epitope H contains an O-linked N-acetylglucosamine (O-GlcNAc) residue in a specific conformation and/or environment recognized by monoclonal antibody H (mAbH). We have previously shown that epitope H is present in more than one polypeptide and in various types of normal and pathological cells. In the present study, we focused on uterine smooth muscle cell tumors and their adjacent normal myometrium to gain further insight into the expression patterns of epitope H in human tissues. The indirect immunoperoxidase method was applied using the mAbH and the monoclonal anti-cytokeratin 8 antibody (AbCK8) in 50 cases of typical uterine leiomyomas and in five cases of uterine leiomyosarcomas, with four cases belonging to Group II A and one to Group III according to Bell et al. [6]. Western immunoblotting was applied using mAbH and AbCK8 in five cases of uterine leiomyomas and their adjacent myometrium. The main results were as follows: (1) epitope H showed intense immunohistochemical expression in 46% (23/50) and moderate expression in 54% (27/50) of uterine leiomyomas, (2) epitope H showed intense immunohistochemical expression in 40% (2/5) and moderate expression in 60% (3/5) of uterine leiomyosarcomas, (3) epitope H showed no difference in the immunohistochemical expression between leiomyomas and their adjacent myometrium and between leiomyosarcomas and their adjacent myometrium, (4) immunohistochemical expression of cytokeratin 8 was not detected in the normal and neoplastic smooth muscle cells, (5) Western immunoblotting showed that in the smooth muscle cells of the myometrium and leiomyomas, epitope H is localized in four polypeptides with molecular weights of 100, 61, 59, and 54 kDa, and (6) Western immunoblotting did not detect cytokeratin 8 in the normal and neoplastic smooth muscle cells. The present results indicate fluctuations of the epitope expression levels in uterine smooth muscle cell tumors and their adjacent myometrium. These fluctuations may be of interest for gaining insight into the pathogenesis of uterine smooth muscle cell tumors, since O-GlcNAc glycosylation is involved in cell cycle and apoptosis pathways and may modify proteins involved in oncogenesis (tumor suppressor proteins and oncoproteins) and proteins with important biological functions such as cytoskeletal proteins, transcription factors, and heat-shock proteins. Furthermore, the present results indicate that cytokeratin 8, without being present in the cells of the myometrium, leiomyomas and leiomyosarcomas, shares its epitope H, which contains its unique sugar O-N-acetylglucosamine residue, with four other unrelated polypeptides produced by the normal and neoplastic smooth muscle cells. This should be considered when using anti-cytokeratin 8 antibodies in immunohistochemistry against smooth muscle cell tumors to avoid false positive immunohistochemical results.
Asunto(s)
Acetilglucosamina/metabolismo , Leiomioma/metabolismo , Leiomiosarcoma/metabolismo , Miometrio/metabolismo , Neoplasias Uterinas/metabolismo , Acetilglucosamina/química , Acetilglucosamina/inmunología , Antígenos de Neoplasias/inmunología , Antígenos de Neoplasias/metabolismo , Biomarcadores de Tumor/metabolismo , Western Blotting , Mapeo Epitopo , Epítopos/química , Epítopos/inmunología , Epítopos/metabolismo , Femenino , Técnica del Anticuerpo Fluorescente Indirecta , Humanos , Queratina-8/inmunología , Queratina-8/metabolismo , Leiomioma/inmunología , Leiomioma/patología , Leiomiosarcoma/inmunología , Leiomiosarcoma/patología , Músculo Liso/inmunología , Músculo Liso/metabolismo , Músculo Liso/patología , Miometrio/inmunología , Neoplasias Uterinas/inmunología , Neoplasias Uterinas/patologíaRESUMEN
Uterine myxoid leiomyosarcoma is a very rare and aggressive variant of uterine sarcoma, of which only 26 cases have been described in the literature published in English. A 59-year-old woman, who had been menopausal for 5 years and had a huge abdominal mass underwent laparotomy; histopathology of the bulky tumor revealed the particular characteristics of a myxoid leiomyosarcoma. Immunohistochemically, Ki-67 contributed toward indicating a malignancy, whereas p53 and progesterone and estrogen receptors were negative. The level of serum Ca125 was high at diagnosis, within normal limits after the fifth cycle of chemotherapy, and subsequently increased again at recurrence. Sixteen months after surgery, the patient died of respiratory failure. Immunohistochemistry and Ca125 levels can aid the diagnosis, management, and prognosis of uterine myxoid leiomyosarcoma.
Asunto(s)
Leiomiosarcoma/patología , Neoplasias Uterinas/patología , Antígeno Ca-125/sangre , Femenino , Humanos , Inmunohistoquímica , Leiomiosarcoma/tratamiento farmacológico , Leiomiosarcoma/inmunología , Persona de Mediana Edad , Pronóstico , Neoplasias Uterinas/tratamiento farmacológico , Neoplasias Uterinas/inmunologíaRESUMEN
The cancer-testis antigen NY-ESO-1 is one of the most promising candidates for generic vaccination of cancer patients. Here we analyzed the CD8(+) T cell response to a NY-ESO-1 peptide vaccine composed of the two previously defined peptides 157-165 and 157-167, administered with GM-CSF as a systemic adjuvant. The NY-ESO-1 peptide vaccine elicited a CD8(+) T cell response directed against multiple distinct epitopes in the 157-167 region, as revealed by using A2/peptide multimers incorporating overlapping A2 binding peptides in this region. However, only a minor fraction of the elicited CD8(+) T cells, namely those recognizing the peptide 157-165 with sufficiently high functional avidity, recognized the naturally processed target on NY-ESO-1(+) tumor cells. In contrast, the majority of peptide 157-165-specific CD8(+) T cells exhibited lower functional avidity and no tumor reactivity. In addition, vaccine-elicited CD8(+) T cells specific for other overlapping epitopes in the 157-167 region failed to significantly recognize NY-ESO-1-expressing tumor targets. Thus, because of the complexity of the CD8(+) T cell repertoire that can be elicited by vaccination with synthetic peptides, a precise definition of the targeted epitope, and hence, of the corresponding peptide to be used as immunogen, is required to ensure a precise tumor targeting.